We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 15, 2021

Radiotherapy Plus PCV vs Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Radiotherapy-PCV Versus Radiotherapy-Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicentre Analysis of the French POLA Cohort
Oncologist 2021 Feb 01;[EPub Ahead of Print], V Esteyrie, C Dehais, E Martin, C Carpentier, E Uro-Coste, D Figarella-Branger, C Bronniman, D Pouessel, DL Ciron, F Ducray, EC Moyal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading